Editas Medicine Reports Inducement Grants to New Chief Medical Officer

Editas Medicine (EDIT) granted an inducement stock option award to its newly appointed Chief Medical Officer, Daniel Ory, M.D., in accordance with Nasdaq Listing Rule 5635(c)(4).

Rhea-AI Summary

Editas Medicine (EDIT) granted an inducement stock option award to its newly appointed Chief Medical Officer, Daniel Ory, M.D., in accordance with Nasdaq Listing Rule 5635(c)(4).

The option covers up to 950,000 shares of Editas Medicine common stock at an exercise price of $3.03 per share, equal to the closing price on the grant date. The award vests over four years, with 25% of the shares vesting on the 15th day of the month immediately following the first anniversary of Dr. Ory’s start date, and the remaining 75% vesting ratably at the end of each subsequent month, contingent on his continued service with the company.

News Explained

The disclosed grant is an option rather than an immediate share issuance: it could eventually add up to 950,000 common shares, while four-year, service-conditioned vesting means the potential ownership dilution is not committed all at once.

Key Figures

Stock option shares: 950,000 shares Exercise price: $3.03 per share Vesting period: 4 years +1 more

Stock option shares

950,000 shares

Inducement award to newly appointed Chief Medical Officer

Exercise price

$3.03 per share

Stock option grant

Vesting period

4 years

Stock option grant

Initial vesting

25 percent of shares

Vests after the first anniversary of the start date

Historical Context

1 past event · Latest: Sep 08

1 event

1. Sep 08

   Management appointment

   24h Move

   -6.2%

   Appointment established the employment relationship preceding the inducement option grant.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

inducement award, stock option, nasdaq listing rule 5635(c)(4), vesting

4 terms

inducement award financial

"announced the grant of an inducement award to the Company’s newly appointed"

An inducement award is a special cash or equity payment given to a new hire—often an executive or key employee—outside the company’s regular pay plans to persuade them to join. Think of it like a signing bonus that can align the new person’s goals with shareholders but also represents a cost and can reduce existing owners’ percentage of the company, so investors watch these awards for their impact on ownership and future performance.

stock option financial

"the Editas Medicine Board of Directors approved a stock option grant"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

vesting financial

"and vests over four years, with 25 percent of the shares vesting"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, today announced the grant of an inducement award to the Company’s newly appointed Chief Medical Officer, Daniel Ory, M.D. In connection with Dr. Ory’s appointment, the Editas Medicine Board of Directors approved a stock option grant to Dr. Ory as an inducement material to Dr. Ory entering into employment with Editas Medicine in accordance with Nasdaq Listing Rule 5635(c)(4).  The stock option provides for the purchase of up to 950,000 shares of Editas Medicine common stock at a price of $3.03 per share, the closing price per share of Editas Medicine common stock as reported by Nasdaq on the date of grant, and vests over four years, with 25 percent of the shares vesting on the 15^th day of the month immediately following the first anniversary of Dr. Ory’s start date, and the remainder vesting ratably at the end of each subsequent month thereafter, subject to Dr. Ory’s continued service relationship with Editas Medicine through the applicable vesting dates. 

About Editas Medicine
As a pioneering gene editing company, Editas Medicine is focused on translating the power and potential of CRISPR genome editing systems into a robust pipeline of transformative in vivo medicines for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize durable, precision in vivo gene editing medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute’s Cas12a patent estate and Broad Institute and Harvard University’s Cas9 patent estates for human medicines.

Investor and Media Contacts: 

ir@editasmed.com
media@editasmed.com

Investor and Media Contacts:
ir@editasmed.com
media@editasmed.com

FAQ

How is the stock option grant to Editas Medicine’s new CMO structured?

The stock option gives Daniel Ory, M.D., the right to purchase up to 950,000 shares of Editas Medicine common stock at an exercise price of $3.03 per share, which was the closing price on the grant date. The option vests over four years: 25% of the shares vest on the 15th day of the month immediately following the first anniversary of his start date, and the remaining 75% vest in equal installments at the end of each subsequent month, subject to his continued service with the company.

Under what rule is the inducement award to the new Chief Medical Officer granted?

The Editas Medicine board approved the stock option grant to Daniel Ory, M.D., as an inducement material to his entering into employment with the company, in accordance with Nasdaq Listing Rule 5635(c)(4).